Search

Your search keyword '"Stock, Wendy"' showing total 2,315 results

Search Constraints

Start Over You searched for: Author "Stock, Wendy" Remove constraint Author: "Stock, Wendy"
2,315 results on '"Stock, Wendy"'

Search Results

51. Structural racism is a mediator of disparities in acute myeloid leukemia outcomes

52. Air Pollutant Impact on Disease Characteristics and Outcomes in Patients with Acute Myeloid Leukemia

53. Data from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis

54. Supplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis

55. Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation

56. Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL

57. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy

62. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

64. Adoption of pediatric‐inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population‐based study

65. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR

66. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

68. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia

70. Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study

72. Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)

73. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial

74. Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

75. Real World Outcomes for AYA Patients with Relapsed/Refractory B-Cell ALL Receiving CD19-Directed CAR T-Cell Therapy

76. The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

77. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial

78. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.

79. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665

80. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

81. Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis

84. Single cell dissection of developmental origins and transcriptional heterogeneity in B-cell acute lymphoblastic leukemia

86. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

87. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

88. Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival

89. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia

90. Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia

91. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults

92. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy

96. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

98. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

100. MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia

Catalog

Books, media, physical & digital resources